Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
DRAXIMAGE MDP-25 vs TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Technetium Tc 99m albumin aggregated is a radiopharmaceutical that localizes in the pulmonary capillary bed by capillary blockade, allowing for lung perfusion imaging. The aggregated albumin particles are trapped in the pulmonary capillaries, and the Tc 99m emits gamma radiation detectable by gamma cameras.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
1-4 mCi (37-148 MBq) intravenous injection for lung perfusion imaging. Single dose per imaging session.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Physical half-life of Tc-99m is 6.02 hours; biological half-life of aggregated albumin in lungs is 2-4 hours due to enzymatic degradation and clearance.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Renal: 30-40% within 24 hours (free pertechnetate); fecal: <1% (minor); remainder accumulated in reticuloendothelial system with slow release.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical